Therapeutic Intranasal Vaccine HB-ATV-8 Prevents Atherogenesis and Non-alcoholic Fatty Liver Disease in a Pig Model of Atherosclerosis

Gutiérrez-Vidal, Roxana; Delgado–Coello, Blanca; Méndez-Acevedo, Kevin Manuel; Calixto-Tlacomulco, Sandra; Damián-Zamacona, Salvador; Mas‐Oliva, Jaime

doi:10.1016/j.arcmed.2019.01.007

Cited by 8 publications

(4 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous study in our laboratory has demonstrated that the nasal administration of HB-ATV-8, containing Tzeaxs and Helix-Y 12 , reduces hypertriglyceridemia and vascular and hepatic lesions, including fibrosis, induced by a high-fat diet enriched with cholesterol in pigs and rabbits [ 29 , 30 ]. In this line, PPAR α agonists are useful drugs for reducing serum triglycerides [ 63 ].…”

Section: Discussionmentioning

confidence: 99%

“…The HB-ATV-8 nanoparticles induce mild cholesteryl-ester transfer protein antibodies production, explaining in part the observed effect. However, the protective effect is present even without antibody production [ 29 ]. Hence, we suggest that peptide Helix-Y 12 and the lipid components of the nanoparticles could participate directly in the biological effect.…”

Section: Introductionmentioning

confidence: 99%

“…We have previously shown that HB-ATV-8 lipid nanoparticles have a protective effect against atherosclerotic lesions and NAFLD induced by a high-fat diet in pigs and rabbits [29,30]. The nanoparticles are mainly composed of membrane lipids of Thermus aquaticus and an amphipathic peptide (Cys+ the last 11 residues of the cholesteryl-ester transfer protein, called Helix-Y 12 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Peptide Helix-Y12 as Potential Effector for Peroxisome Proliferator-Activated Receptors

et al. 2023

Self Cite

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in the regulation of lipids and glucose metabolism, and immune response. Therefore, they have been considered pharmacological targets for treating metabolic diseases, such as dyslipidemia, atherosclerosis, and non-alcoholic fatty liver disease. However, the available synthetic ligands of PPARs have mild to significant side effects, generating the necessity to identify new molecules that are selective PPAR ligands with specific biological responses. This study aimed to evaluate some components of the atheroprotective and hepatoprotective HB-ATV-8 nanoparticles [the amphipathic peptide Helix-Y12, thermozeaxanthin, thermozeaxanthin-13, thermozeaxanthin-15, and a set of glycolipids], as possible ligands of PPARs through blind molecular docking. According to the change in free energy upon protein–ligand binding, ∆Gb, thermozeaxanthins show a more favorable interaction with PPARs, followed by Helix-Y12. Moreover, Helix-Y12 interacts with most parts of the Y-shaped ligand-binding domain (LBD), surrounding helix 3 of PPARs, and reaching helix 12 of PPARα and PPARγ. As previously reported for other ligands, Tyr314 and Tyr464 of PPARα interact with Helix-Y12 through hydrogen bonds. Several PPARα’s amino acids are involved in the ligand binding by hydrophobic interactions. Furthermore, we identified additional PPARs’ amino acids interacting with Helix-Y12 through hydrogen bonds still not reported for known ligands. Our results show that, from the studied ligand set, the Helix-Y12 peptide and Tzeaxs have the most significant probability of binding to the PPARs’ LBD, suggesting novel ligands for PPARs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Peptide Helix-Y12 as Potential Effector for Peroxisome Proliferator-Activated Receptors

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…As such, micelles-based vaccines may achieve effective prevention and inhibition of atherosclerosis. 129 …”

Section: Organic Nps For Atherosclerosis Treatmentmentioning

confidence: 99%

Advances in imaging and treatment of atherosclerosis based on organic nanoparticles

Han

et al. 2022

APL Bioengineering

View full text Add to dashboard Cite

Atherosclerosis, a systemic chronic inflammatory disease, can lead to thrombosis and vascular occlusion, thereby inducing a series of serious vascular diseases. Currently, distinguishing unstable plaques early and achieving more effective treatment are the two main clinical concerns in atherosclerosis. Organic nanoparticles have great potential in atherosclerotic imaging and treatment, showing superior biocompatibility, drug-loading capacity, and synthesis. This article illustrates the process of atherosclerosis onset and the key targeted cells, then systematically summarizes recent progress made in organic nanoparticle-based imaging of different types of targeted cells and therapeutic methods for atherosclerosis, including optical and acoustic-induced therapy, drug delivery, gene therapy, and immunotherapy. Finally, we discuss the major impediments that need to be addressed in future clinical practice. We believe this article will help readers to develop a comprehensive and in-depth understanding of organic nanoparticle-based atherosclerotic imaging and treatment, thus advancing further development of anti-atherosclerosis therapies.

show abstract

Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis

Chen

Zhang

Millican

et al. 2021

Advanced Drug Delivery Reviews

101

View full text Add to dashboard Cite

Therapeutic Intranasal Vaccine HB-ATV-8 Prevents Atherogenesis and Non-alcoholic Fatty Liver Disease in a Pig Model of Atherosclerosis

Cited by 8 publications

References 105 publications

Peptide Helix-Y12 as Potential Effector for Peroxisome Proliferator-Activated Receptors

Peptide Helix-Y12 as Potential Effector for Peroxisome Proliferator-Activated Receptors

Advances in imaging and treatment of atherosclerosis based on organic nanoparticles

Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis

Contact Info

Product

Resources

About